Endovascular Therapy for Erectile Dysfunction – Who Benefits Most? Insights From a Single-Center Experience

Nicolas Diehm et al. J Endovasc Ther. 2019;26(2)


Supplemental Figure 1. (A) Change of the 15-item International Index of Erectile Function score from baseline to 12 months and differences between subgroups per (B) univariable and (C) multivariable analysis. CAD, coronary artery disease; DCB, drug-coated balloon; DES, drug-eluting stent; PAD, peripheral artery disease; PDE5, phosphodiesterase type 5; RVD, reference vessel diameter. ^aFormer or current smokers. ^bChronic prostatitis, previous prostate surgery, or hypogonadism. ^cBeta-blockers, psychotropic drugs, or thiazide diuretics. ^dPDE5 inhibitors or intracavernosal prostaglandin prior to intervention. ^eDistal pudendal artery or distally located arteries.


Α Change of the IIEF-15 score from baseline to 12 months В Difference in mean (95% CI) Univariable analysis Age > 70 years Age (per 10 years) 6.0 (-1.5 to 14.0) Yes (n=9) No (n=40) 12.2 (6.5 to 18.1) Diabetes mellitus **Diabetes mellitus** Smoker^a 67 (-06 to 137) Yes (n=9) No (n=40) 12.3 (6.4 to 18.1) Hypertension Smoker^a Hyperlipidemia 10.9 (5.8 to 16.0) Yes (n=38) No (n=11) 12.0 (-2.9 to 27.3) PAD or CAD Hypertension Prostatitis, surgery, or hypogonadsmb Yes (n=24) 5.6 (-0.2 to 11.3) 16.5 (8.7 to 24.4) No (n=25)Inhibiting drugs^c Hyperlipidemia PDE5 inhibitors^d Yes (n=17) 12.5 (3.8 to 21.2) No (n=32) 10.5 (4.5 to 16.6) Bilateral PAD or CAD Number of lesions (per lesion) Yes (n=11) 11.4 (0.6 to 22.3) No (n=38)11.3 (5.5 to 16.7) Distal lesion location^e Protatitis, surgery, or hypogonadismb DCB (versus DES) Yes (11) 8.7 (-1.1 to 18.7) No (n=38) 12.3(6.8 to 17.9) Total lesion length (per mm) Inhibiting drugs^C Smallest RVD (per mm) Yes (n=15) 13.3 (3.6 to 22.9) No (n=34) 10.5 (4.4 to 16.3) Smallest acute gain (per mm) PDE5 inhibitors d Yes (n=33) 11.3 (5.1 to 17.4) -20 -10 11.1 (2.1 to 19.9) No (n=16) Bilateral Yes (n=17) 14.2 (4.8 to 23.8) No (n=32) 9.6 (4.0 to 15.1) С > 1 Lesion Yes (n=21) 135 (61 to 211) **Multivariable analysis** No (n=28) 9.4 (2.8 to 16.0) Distal lesion location^e Yes (n=26) 7.4 (0.8 to 14.0) Hypertension No (n=23) 15.5 (8.1 to 22.8) Distal lesion location⁶ Treatment DES (n=29) 12.2 (5.2 to 19.0) DCB (n=13) 3.8 (-5.1 to 12.6) -20 -10 All patients (n=49) 11.2 (6.2 to 16.1) p < 0.001 -10 0 11.2 30

Difference in IIEF-15 change between subgroups

Difference in mean (95% Cl)

р





Endovascular Therapy for Erectile Dysfunction – Who Benefits Most? Insights From a Single-Center Experience

Nicolas Diehm et al. J Endovasc Ther. 2019;26(2)

Supplemental Figure 2. Change in the ability to achieve penetration or to maintain erection based on IIEF questions 3 and 4 of the 15-item International Index of Erectile Function score from baseline to 12 months depending on patient-, lesion-, and procedure-related subgroups per (A) univariable and (B) multivariable analysis. CAD, coronary artery disease; DCB, drug-coated balloon; drug-eluting stent; peripheral DES. PAD, artery disease: PDE5. phosphodiesterase type 5; RVD, reference vessel diameter. ^aFormer or current smokers. ^bChronic prostatitis, previous prostate surgery, or hypogonadism. ^cBeta-blockers, psychotropic drugs, or thiazide diuretics. ^dPDE5 inhibitors or intracavernosal prostaglandin prior to intervention. ^eDistal pudendal artery or distally located arteries.

A Univariable analysis

Difference in change within 1 year between subgroups

IIEF Q3 ability to achieve penetration

IIEF Q4 ability to maintain erection

Age (per 10 years)		-0.37 (-0.89 to -0.15) -0.31 (-0.81 to -0.20)	0.158 0.231
Diabetes mellitus	B	-0.27 (-1.65 to 1.10) -0.71 (-2.00 to 0.59)	0.691 0.276
Smoker ^a		-0.68 (-1.94 to 0.59) -0.56 (-1,77 to 0.65)	0.270 0.353
Hypertension		-1.20 (-2.21 to -0.19) -1.54 (-2.46 to -0.63)	0.020 0.001
Hyperlipidemia		-0.53 (-1.64 to 0.58) -0.12 (-1.19 to 0.95)	0.339 0.818
PAD or CAD		-0.26 (-1.54 to 1.01) -0.53 (-1.78 to 0.72)	0.681 0.397
Prostatitis, surgery, or hypogonadism ^b		-0.70 (-1.99 to 0.59) -1.42 (-2.61 to -0.23)	0.282 0.021
Inhibiting drugs ^c		-0.16 (-1.34 to 1.02) -0.23 (-1.36 to 0.89)	0.790 0.681
PDE5 inhibitors ^d		0.16 (-0.99 to 1.32) 0.61 (-0.48 to 1.70)	0.779 0.264
Bilateral		0.19 (-0.93 to 1.31) 0.15 (-0.92 to 1.22)	0.736 0.779
Number of lesions (per lesion)	_	0.06 (-0.53 to 0.64) 0.06 (-0.50 to 0.62)	0.847 0.837
Distal lesion location ^e		-0.53 (-1.58 to 0.53) -0.13 (-1.16 to 0.90)	0.322 0.801
DCB (versus DES)		-0.10 (-1.40 to 1.20) -0.20 (-1.49 to 1.09)	0.873 0.754
Total lesion length (per mm)	=	0.03 (-0.01 to 0.07) 0.02 (-0.02 to 0.06)	0.190 0.238
Smallest RVD (per mm)		-0.37 (-1.05 to 0.30) -0.02 (-0.67 to 0.63)	0.270 0.956
Smallest acute gain (per mm)		-0.18 (-1.42 to 1.05) -0.09 (-1.28 to 1.10)	0.768 0.878
-3	0 2		

Difference in mean (95% Cl)

р

B Multivariable analysis

